作者：
Patricio,Serra-Bellver [1]
;
Judith M,Versluis [2]
;
Honey K,Oberoi [3]
;
Cong,Zhou [4]
;
Timothy D,Slattery [5]
;
Yasir,Khan [5]
;
James R,Patrinely [6]
;
Inês,Pires da Silva [7]
;
C,Martínez-Vila [8]
;
Natalie,Cook [9]
;
Donna M,Graham [9]
;
Matteo S,Carlino [7]
;
Alexander M,Menzies [10]
;
Ana M,Arance [11]
;
Douglas B,Johnson [6]
;
Georgina V,Long [10]
;
Lisa,Pickering [5]
;
James M G,Larkin [5]
;
Christian U,Blank [2]
;
Paul,Lorigan [9]
作者单位：
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: p.serra@nhs.net.
[1]
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
[2]
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
[3]
Cancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, United Kingdom.
[4]
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, United Kingdom.
[5]
Department of Medical Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
[6]
Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Westmead and Blacktown Hospital, Sydney, Australia.
[7]
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
[8]
Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, United Kingdom.
[9]
Melanoma Institute Australia, The University of Sydney and the Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
[10]
Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
[11]
DOI
10.1016/j.ejca.2022.09.004
PMID
36215945
发布时间
2022-12-14
换一批
换一批
